Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 in PD-L1 negative advanced NSCLC
NCT05690945Phase 3Active, not recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Jun 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Qilu Pharmaceutical. Started Feb 2023; status: active, not recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05690945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05690945.